Ondine Biomedical (FRA:VF5) EBIT: €-18.45 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:VF5 Ondine Biomedical Inc FRA:VF5
41 GF Score
Price €0.13
GF Value €0.09
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Ondine Biomedical EBIT?

Ondine Biomedical FRA:VF5 +2.34% 41 EBIT is €-18.45 Mil as of Dec. 2025. GuruFocus rates FRA:VF5 with a GF Score™ of 41/100 and a GF Value™ of €0.09 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Ondine Biomedical's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was €-10.49 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €-18.45 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Ondine Biomedical's annualized ROC % for the quarter that ended in Dec. 2025 was -486.59%. Ondine Biomedical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -2,939.87%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Ondine Biomedical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -24.40%.


Ondine Biomedical  (FRA:VF5) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Ondine Biomedical's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-21.602 * ( 1 - 0% )/( (3.411 + 5.468)/ 2 )
=-21.602/4.4395
=-486.59 %

where

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Ondine Biomedical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-20.976/( ( (0.768 + max(-3.524, 0)) + (0.659 + max(-4.851, 0)) )/ 2 )
=-20.976/( ( 0.768 + 0.659 )/ 2 )
=-20.976/0.7135
=-2,939.87 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.201 + 0.84 + 0.179) - (2.318 + 0 + 2.426)
=-3.524

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.254 + 1.127 + 0.258) - (1.907 + 0 + 4.583)
=-4.851

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Ondine Biomedical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-18.451/75.604
=-24.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ondine Biomedical EBIT Related Terms


Ondine Biomedical EBIT Historical Data

* Premium members only.

The historical data trend for Ondine Biomedical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ondine Biomedical EBIT Chart

Ondine Biomedical Annual Data
Trend Dec10 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -33.79 -13.44 -9.83 -12.77 -18.26

Ondine Biomedical Semi-Annual Data
Jun09 Dec09 Jun10 Dec10 Jun11 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.44 -5.25 -7.58 -7.96 -10.49

FRA:VF5 vs VRTX, REGN, RVMD: EBIT Comparison

For the Biotechnology subindustry, Ondine Biomedical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ondine Biomedical EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ondine Biomedical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Ondine Biomedical's EV-to-EBIT falls into.


FRA:VF5
41GF Score
Ondine Biomedical Inc FRA:VF5
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ondine Biomedical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-18.45 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-18.45 Mil mean?
Ondine Biomedical (FRA:VF5) has a EBIT of €-18.45 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Ondine Biomedical.
Is Ondine Biomedical's EBIT too high?
Ondine Biomedical's current EBIT is €-18.45 Mil. Overall, Ondine Biomedical has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ondine Biomedical's EBIT compare to VRTX and REGN?
Ondine Biomedical's EBIT of €-18.45 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Ondine Biomedical. Ondine Biomedical's current EBIT is €-18.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ondine Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Ondine Biomedical (FRA:VF5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.09, compared to a current price of €0.13 — trading 45.6% above its estimated fair value. The current EBIT is €-18.45 Mil. Ondine Biomedical's overall GF Score™ is 41/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Ondine Biomedical (FRA:VF5), the current EBIT is €-18.45 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ondine Biomedical (FRA:VF5) Overvalued in 2026?

Based on GuruFocus' analysis, Ondine Biomedical stock appears to be overvalued. The current stock price of €0.13 is trading 45.6% above its estimated GF Value™ of €0.09. GuruFocus considers Ondine Biomedical to be Significantly Overvalued.

Key valuation signals for FRA:VF5:

  • EBIT: €-18.45 Mil
  • GF Value™: €0.09 vs. price of €0.13 (45.6% above fair value)
  • GF Score™: 41/100 with 7 warning signs

No single metric tells the full story. See the FRA:VF5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ondine Biomedical Business Description

Other Exchanges OBIMF:USAOBI:UK
Address 1100 Melville Street, Suite 888, Vancouver, BC, CAN, V6E4A6
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.
41GF Score

Get the complete analysis for FRA:VF5

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.13
Price
€0.09
GF Value